BeOne Medicines (BEIGF) Receivables - Net (2017 - 2026)

BeOne Medicines (BEIGF) has 10 years of Receivables - Net data on file, last reported at $938.0 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $938.0 million, up 30.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $938.0 million (up 30.78% YoY), and the FY2025 annual result was $865.1 million, up 27.92% from the prior year.
• Receivables - Net improved to $938.0 million in Q1 2026 per BEIGF's latest filing, from $865.1 million in the prior quarter.
• Over five years, Receivables - Net peaked at $938.0 million in Q1 2026 and troughed at $172.3 million in Q2 2022.
• A 5-year average of $492.1 million and a median of $435.3 million in 2024 frame the typical range for Receivables - Net.
• On a YoY basis, Receivables - Net climbed as much as 133.45% in 2022 and fell as far as 64.16% in 2022.
• A 5-year view of Receivables - Net shows it stood at $173.2 million in 2022, then soared by 106.75% to $358.0 million in 2023, then surged by 88.89% to $676.3 million in 2024, then climbed by 27.92% to $865.1 million in 2025, then gained by 8.43% to $938.0 million in 2026.
• Business Quant data shows BEIGF's Receivables - Net at $938.0 million in Q1 2026, $865.1 million in Q4 2025, and $863.3 million in Q3 2025.